Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.

ABSTRACT:

Background

Randomized trial data demonstrate the gain of extended duration anticoagulation in patients with venous thromboembolic events (VTE); however, real-world data are limited.

Objectives

Assess the risk of recurrent VTE and major bleeding in a real-world setting of patients who experienced unprovoked VTE and received extended treatment with rivaroxaban.

Methods

US claims databases (February 2011-April 2015) were used in this retrospective study. The study population included adult patients initiated on rivaroxaban within 7 days after their first unprovoked VTE (ie, deep vein thrombosis, pulmonary embolism) and received ≥3 months continuous rivaroxaban treatment (index date: end of 3-month treatment). Patients who were treated beyond 3 months formed the continued

SUBMITTER: Berger JS 

PROVIDER: S-EPMC6055557 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature